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Abstract: The Medication Quantification Scale III (MQS) is a tool to represent the negative
impact of medication. A reduction in medication can serve as an indicator to evaluate treatment
success. However, no cut-off value has yet been determined to evaluate whether a decrease in
medication is clinically relevant. Therefore, the objective is to estimate the thresholds for the MQS
and morphine milligram equivalents (MMEs) that best identify a clinically relevant important
improvement for patients. Data from the Discover registry, in which patients with failed back surgery
syndrome were treated with high-dose spinal cord stimulation, were used. Patient satisfaction was
utilized to evaluate a clinically important outcome 12 months after stimulation. Anchor-based and
distribution-based methods were applied to determine the minimal clinical important difference
(MCID). Distribution-based methods revealed a value of 4.28 for the MQS and 33.61 for the MME as
MCID. Anchor-based methods indicated a percentage change score of 41.2% for the MQS and 28.2%
for the MME or an absolute change score of 4.72 for the MQS and 22.65 for the MME. For assessing
a treatment outcome, we recommend using the percentage change score, which better reflects a
clinically important outcome and is not severely influenced by high medication intake at baseline.
Keywords: minimal clinically important difference; clinical importance; responsiveness
1. Introduction
Spinal cord stimulation (SCS) is a minimal-invasive treatment option that is recommended for
patients with failed back surgery syndrome (FBSS) in the case that conservative treatment does not
provide sufficient pain relief. This condition is characterised by lumbar or cervical pain of unknown
origin, either persisting despite surgical intervention or appearing after surgical intervention for spinal
(origin) pain originally in the same topographical distribution [1,2]. High-dose SCS (HD-SCS) is one of
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the new paradigms within the field of spinal cord stimulation that relies on delivering high energy at a
subsensory threshold, with the main focus of increasing the impact of electrical charge delivery to the
spinal cord [3].
Up till now, the success of SCS was mainly focused on obtaining sufficient pain relief. Nevertheless,
reimbursement rules are also focusing on pain medication reductions, as, for example, at least 50%
pain reduction and 50% reduction in pain medication use should be obtained in Belgium to consider a
trial period successful. Additionally, the terms holistic responder and multidimensional responder
index were recently launched, which comprise a combination of several factors among which pain
relief, disability, and quality of life are outcome measures for SCS [4,5]. This clearly indicates that there
is an ongoing reformulation of the definition of success in the field of neuromodulation towards a
more holistic perspective [6,7]. However, when constructing this definition, clinicians are confronted
with a wide variety of available cut-off values that could be applied. Moreover, challenges exist
in determining the clinical significance of a change in outcome measurements from a patient’s
perspective [8]. One possible solution to handle this issue is by relying on minimal clinical important
difference (MCID) values. An MCID can be considered as the smallest change or difference in an
outcome measure that is perceived as beneficial and would lead to a change in the patient’s medical
management, assuming an absence of excessive side effects and costs [9].
Although the use of opioids is controversial and currently only recommended for short time
periods, opioids are still broadly used in the treatment of patients with FBSS [10]. A recent systematic
review indicated that SCS is significantly associated with decreased medication use and opioid
consumption compared to the best medical treatment [11]. As such, reducing medication use is
factually a component of treatment success and should be consistently quantified. The Medication
Quantification Scale III (MQS) is a tool specifically designed to quantify pain medication regimens by
providing a numerical output that represents the negative impact of each medication in a wide variety
of pain conditions [12,13]. Nevertheless, no clinical important cut-off values for the MQS or morphine
milligram equivalents (MMEs) have been proposed yet. Therefore, the objective of the present study is
to estimate the thresholds for the MQS and MME that best identify FBSS patients who perceived a
clinically important outcome following HD-SCS stimulation.
2. Experimental Section
2.1. Data
In this study, data from a prospective multicenter registry-based cohort study towards the
effectiveness of HD-SCS were used. The protocol of this real-world registry (called Discover) was
registered on clinicaltrials.gov (NCT02787265) on 1 July 2016 and previously published [14]. In this
registry, 272 FBSS patients were recruited between October 2016 and November 2019 in 15 Belgian
neuromodulation centres and 1 centre in France. FBSS patients with a numerical rating scale (NRS)
score ≥5/10 for leg and/or back pain for at least 6 months and who were suitable for HD-SCS were
eligible to participate. FBSS patients with a numerical rating scale (NRS) score >3/10 for leg and/or back
pain who were treated with standard SCS and dissatisfied with standard SCS as treatment were also
eligible to participate. All patients received high-dose spinal cord stimulation (HD-SCS) as treatment.
Three follow-up visits took place in the following year, namely, after one month, three months,
and twelve months of HD-SCS.
The study was conducted according to the revised Declaration of Helsinki (1998). The study
protocol was approved by the ethics committee of Universitair Ziekenhuis Brussel (B.U.N. 143201629180)
and the ethics committees of each participating centre. All patients provided written informed consent
before enrolment in this study.
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2.2. Patient-Reported Outcome Measures
Patients were asked to provide the details of all pain medication, with corresponding frequency
and amount per day, at each visit. The MQS is designed to quantify pain medication regimens in a
wide variety of pain conditions [12]. It provides a numerical output that represents the negative impact
of each medication [13]. For each medication, an MQS score is calculated by multiplying a detriment
weight for a given pharmacologic class with a score for dosage [15]. Medication is subdivided into
five classes: nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, neuropathic pain
medications (antidepressants and anticonvulsants), benzodiazepines, and opioids. All calculated
values are summed to obtain a total MQS score. For opioids, MMEs were calculated as well. For MMEs,
the total quantity is multiplied by the strength per unit and then multiplied by the opioid-specific
morphine conversion factor. Morphine conversion factors from the CDC were used [16].
Patient satisfaction with HD-SCS was measured with a 5-point Likert scale (not at all satisfied,
slightly satisfied, neutral, very satisfied, and extremely satisfied) at the follow-up visits. Patients who
rated themselves as extremely satisfied or very satisfied at a 12-month follow-up were considered
to have gained a clinically important outcome following SCS implantation (better), whereas other
patients were considered to have not benefited from their treatment (worse/neutral) [17].
2.3. Statistical Analysis
All analyses were performed in R Studio version 1.2.5019 (R version 3.6, Boston, MA, USA,) and
SAS version 9.4 (100 SAS Campus Drive Cary, NC, USA). Both for MME and MQS scores, three different
calculations were evaluated: (1) the raw scores at baseline and 12-month follow-up, (2) the absolute
change score (i.e., the absolute change from baseline minus follow-up, and (3) the percentage change
score (i.e., the relative change score calculated as ((baseline score—follow-up score)/baseline score)
× 100). In total, five different approaches were used to determine the MCID of which two are
distribution-based methods (standard deviation (SD) and effect sizes) and three are anchor-based
methods (within-patients change score, between-patients change score, and sensitivity/specificity).
Distribution-based methods rely on statistical parameters reflecting the statistical variation and
measurement accuracy of the outcome [18]. Anchor-based methods use an explicit scale which is
referred to as an “anchor”, meaning that after treatment, this scale serves as an external standard
against which changes in the outcome score can be compared [19]. The first method to define
the MCID is by calculating the standard deviation of the baseline score. The calculation of the
MCID = 0.5 × SD, where SD represents the SD of the baseline score of the patient population being
studied [20]. This method is based on a systematic review of studies that have calculated the MCID
with different measurement instruments, whereby it was revealed that the MCID converged roughly
to half the SD of the baseline score, regardless of the methodology that was used to calculate the
MCID [20]. The second method is based on effect sizes (i.e., a standardised measure of change obtained
by dividing the absolute difference in scores from baseline to follow-up by the SD of the baseline
scores). Regarding MCID, the change in scores corresponding to the small effect size is considered the
MCID [21]. Thus, multiplying the SD of the baseline scores by 0.2 (denoting a small effect size) provides
the MCID (i.e., MCID = 0.2 × SD) [22]. The third method to determine the MCID is an anchor-based
method, whereby the absolute and relative changes in mean scores for patients categorised as “better”
are used as MCID values [18] (within-patient change score). In the fourth method, the MCID is defined
as the difference in the absolute change score of the patients classified as “better” and the group
classified as “worse/neutral” [21] (between-patient change score). The fifth method consists of selecting
the value that allows for the best discrimination between “better” and “worse/neutral” (i.e., the score
that produces the best results concerning sensitivity and specificity) as MCID. The value with equal
sensitivity and specificity is chosen as the MCID value [21].
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3. Results
3.1. Patient Characteristics
Baseline data on medication use were available for 259 patients (43.6% males, 56.4% females).
Patients had a mean age of 54.7 years (SD: 11.8 years). At 12-month follow-up, the data of 130 patients
were available, of which 0.8% of patients were not at all satisfied with HD-SCS, 18.5% were slightly
satisfied, 8.5% were neutral, 31.5% were very satisfied, and 40.8% were extremely satisfied. Mean MQS
score at baseline was 10.99 (95% CI from 9.94 to 12.03) and 6.57 (95% CI from 5.39 to 7.75) at 12-month
follow-up. The mean MME score at baseline was 43.35 (95% CI from 35.12 to 51.58) and 22.50 (95% CI
from 15.65 to 29.35) at 12-month follow-up.
3.2. Distribution-Based Methods
In the first method, the MCID is equal to 0.5 times the standard deviation of the baseline score.
This resulted in a value of 4.28 for the MQS and 33.61 for the MME. In the second method, which is
based on a small effect size, the proposed MCID value was calculated by multiplying the standard
deviation of the baseline score by 0.2. This resulted in an MCID value of 1.71 for the MQS and 13.45 for
the MME.
3.3. Anchor-Based Methods
Within the third method, absolute and percentage change scores for patients within the “better”
group are considered as MCID values. This resulted in an absolute MCID value of 4.72 for the MQS
(Figure 1) and 22.65 for the MME.
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is the between-patient change score. 
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were proposed (Figure 2).  
Figure 1. Boxplot of Medication Quantification Scale III (MQS) absolute change score between baseline
and 12-month follow-up. On the y-axis, baseline MQS score minus follow-up MQS score is presented.
On the x-axis, “better” and “worse/neutral” levels are presented based on patient satisfaction scores.
Within the boxex, the median is allocated with a black line and the mean with a black circle. The white
circles on the plot are presenting more extreme data observations. Within-patient change score is the
mean absolute change score for the “better” group. The difference in the absolute change score of
the patients classified as “better” and the group classified as “worse/neutral” is the between-patient
change score.
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When calculating with percentage changes, values of 41.2% for the MQS and 28.2% for the MME
were proposed (Figure 2).J. Clin. Med. 2020, 9, x FOR PEER REVIEW 5 of 9 
 
Figure 2. Scatterplot of MQS (A) and morphine milligram equivalent (MME) (B) percentage change 
score between baseline and 12-month follow-up, separated according to patient satisfaction. The 
colours represent the different levels of patient satisfaction. Levels on the right side of the solid black 
line are considered clinically successful and categorised as “better”. On the y-axis, percentage scores 
between baseline and 12-month follow-up are presented, which were calculated as follows: ((baseline 
score − follow-up score)/baseline score) × 100). Positive scores indicate an improvement at follow-up 
compared to baseline, while negative percentages indicate a worse outcome at follow-up compared 
to baseline. MCID values were calculated and are presented on the plot by the dashed blue lines. For 
MQS, the MCID is located at 41.18% and for the MME at 28.20%. Abbreviations. MME: morphine 
milligram equivalents ; MQS: Medication Quantification Scale III. 
In the fourth method, the MCID is defined as the difference in the absolute change score of the 
patients classified as “better” and the group classified as “worse/neutral” (between-patient change 
score), which resulted in an MCID value of 2.03 for the MQS (Figure 1) and 15.18 for the MME. The 
fifth method consists of selecting the value that allows for the best discrimination between “better” 
and “worse/neutral” as MCID, which resulted in a proposed MCID value of 1.4 for absolute changes 
and 30% as percentage change score for the MQS. For the MME, 8 was proposed as the MCID value 
for absolute changes and 17% for percentage change scores. Table 1 presents an overview of all 
proposed MCID values. 
Table 1. Distribution- and anchor-based proposed MCID values for the MQS and MME in patients 
with FBSS after treatment with high-dose spinal cord stimulation (HD-SCS). 




Standard deviation MCID = 0.5 × 
SDbaseline 4.28 33.61 
Effect size 
MCID ≥ 0.2 × 





Absolute change score 
for “better” group 4.72 22.65 
Percentage change 











Figure 2. Scatterplot of MQS (A} and morphine milligram equivalent (M E) (B) percentage change
score b tween baseline a d 12-month follow-up, separated ccor ing t patient satisfaction. The colours
represent the different levels of pati nt satisfaction. Levels on the righ side of the s lid black line
are considered clinical y successful and c tegorised as “better”. On the y-axis, percentage scores
between baseline and 12-month foll w-up are presented, which were calculated as foll ws: ((baseline
score − foll w-up score)/baseline score) × 100). Positive scores indicate an improvement at follow-up
compared to baseline, while negative percentages indicate a worse outcome at follow-up compared
to baseline. MCID values were calculated and are presented on the plot by the dashed blue lines.
For MQS, the MCID is located at 41.18% and for the MME at 28.20%. Abbreviations. MME: morphine
milligram equivalents; MQS: Medication Quantification Scale III.
In the fourth method, the MCID is defined as the difference in the absolute change score of the
patient classified as “better” d the gro p classified as “worse/neutral” (between-patient change
score), which resulted in an MCID value of 2.03 for the MQS (Figur 1) and 15.18 f r the MME. Th fifth
method consists of selecting the value t at allows for the best discrimination between “better” and
“worse/neutral” as MCID, which resulted in a proposed MCID value of 1.4 for absolute changes and
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Table 1. Distribution- and anchor-based proposed MCID values for the MQS and MME in patients
with FBSS after treatment with high-dose spinal cord stimulation (HD-SCS).
Approach Method Calculation MQS MME
Distribution-based
methods
Standard deviation MCID = 0.5 ×SDbaseline 4.28 33.61







































Abbreviations. FBSS: Failed Back Surgery Syndrome; MCID: minimal clinical important difference; MME: morphine
milligram equivalent; MQS: Medication Quantification Scale III; SD: standard deviation.
4. Discussion
In this study, we determined the MCID for medication use in patients with FBSS who are treated
with HD-SCS. As already indicated by several other researchers, this study confirms that when applying
several methods to determine MCID, all methods will provide different cut-off values [17,23]. The variety
in obtained values in anchor-based methods is probably due to the criterion scale and the arbitrary
selection of scale levels (i.e., the grouping of the levels) [21]. Distribution-based methods, on the other
hand, depend on the measure of statistical variability that is used, thereby neglecting clinical importance
and consecutively ignoring the purpose of the MCID, which is to denote a clinically important difference
instead of a statistically significant difference [21]. Therefore, clinicians and researchers should carefully
evaluate which MCID value is the most suitable in their specific context. In longitudinal designs,
anchor-based methods might better reflect clinical importance, while distribution-based methods
might be better suited for cross-sectional designs.
Medication use was globally evaluated with the MQS, combined with a specific focus on opioids
through the MME. The opioid crisis is still a major global public health concern [24], with an increase in
the number of opioid prescriptions during the last decade [25]. Due to this epidemic, many researchers
only focus on opioids instead of taking neuropathic pain medication, muscle relaxants, and other
categories into account. Moreover, for chronic noncancer pain, recommendations and guidelines strive
towards avoiding doses above 90 MME [26–28], wherefore a clinically important change in MME
might be very relevant for clinicians that mainly aim to focus on opioid reduction.
One of the methods to determine the MCID relies on sensitivity and specificity. Specifically,
in the context of MCID, sensitivity is the proportion of patients who report an improvement in patient
satisfaction and whose medication scores are above the threshold MCID value. Specificity is the
proportion of patients who do not report an improvement in patient satisfaction and whose medication
scores are below the threshold MCID value [21]. A sensitivity of 1 indicates that all true positives are
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identified, whereas a specificity of 1 indicates that all true negatives are identified. For both opioid use
and global medication use, sensitivity and specificity were rather low, wherefore this method might
not be the most suitable in this case.
In determining the MCID, one needs to take into account that there is an association between
baseline scores and change scores, such that patients with greater baseline levels of disability
reveal a greater improvement after follow-up [29,30]. Similar results were found for pain intensity,
whereby patients with a high baseline level of pain on the NRS, who experienced either a slight
improvement or a higher level of response, had absolute raw and percentage changes greater than
patients with lower baseline scores [31]. Previously, it was already stated that the use of the MCID
value alone might be limited when determining treatment effects, due to baseline dependency of
the sample [32]. One possible solution to manage this association is by using the percentage change
instead of the absolute change scores to determine an MCID value. As such, we propose to work with
percentage change scores, whereby an MCID value of 41.2% should be obtained for the MQS and 28.2%
for the MME.
The MCID in this study is based on a cohort study of patients with FBSS. A larger sample
size would have allowed for a better generalisation of the results and an improvement in precision.
Additionally, the design of the Discover registry did not allow us to use methods that rely on the
standard error of measurement, which is also considered a proxy for the MCID [33].
5. Conclusions
For estimating “a successful outcome” of HD-SCS in patients with FBSS, according to a clinically
relevant point of view instead of a statistical point of view, a percentage change of 41.2% should be
reached for the MQS and 28.2% for the MME.
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